Teleflex has entered into a definitive agreement to divest our Interventional Urology portfolio, including the UroLift System™, Barrigel™ rectal spacer, Deflux™ injectable gel, and Solesta™ bulking agent, to Intersurgical®.

This transaction is expected to close in the second half of 2026, subject to customary regulatory approvals and other closing conditions.

We’re excited about this opportunity and remain committed to providing the same high-quality products, reliable service, and on-time delivery our customers expect. We will keep our physicians and patients informed throughout the transition. Please feel free to contact your sales representative with any questions or concerns.

Share this article

Explore Other Articles

Teleflex signs MoU with Fortis Hospitals in India to create a UroLift™ Center of Education
Read More
Clinical Study Proves UroLift® System Is Effective in Improving Benign Prostatic Hyperplasia (BPH) Symptoms
Read More
Sexual Function Improved and Preserved with the UroLift® System, a Proven Alternative to BPH Medications
Read More
Address BPH Symptoms Early to Prevent Permanent Bladder Damage and Improve Long-Term Quality of Life
Read More